R Thimme

Summary

Affiliation: University Hospital
Country: Germany

Publications

  1. ncbi T cell responses in hepatitis C: the good, the bad and the unconventional
    Paul Klenerman
    NIHR Biomedical Research Centre, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK
    Gut 61:1226-34. 2012
  2. ncbi [Hepatology 2007]
    R Thimme
    , Freiburg, Germany
    Dtsch Med Wochenschr 132:1392-5. 2007
  3. ncbi Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma
    Robert Thimme
    Department of Medicine II, University Hospital Freiburg, Freiburg, Germany
    Hepatology 48:1821-33. 2008
  4. ncbi [Hepatitis B viral load as a risk factor for liver cirrhosis]
    R Thimme
    Abteilung Innere Medizin II,
    Dtsch Med Wochenschr 133:1589-91. 2008
  5. ncbi [Hepatology 2008]
    R Thimme
    Abteilung Innere Medizin II, , Hugstetter Strasse 55, 79106 Freiburg
    Dtsch Med Wochenschr 133:1366-9. 2008
  6. ncbi [The role of the virus specific T-cell response in acute and chronic HBV and HCV infection]
    E Panther
    Abteilung Innere Medizin II, , Germany
    Z Gastroenterol 42:39-46. 2004
  7. ncbi [Chronic hepatitis B]
    R Thimme
    , Abteilung Innere Medizin II, Hugstetter Strasse 55, 79106 Freiburg
    Dtsch Med Wochenschr 133:135-8. 2008
  8. ncbi [Cholestatic liver diseases]
    R Thimme
    , Abteilung Innere Medizin II
    Ther Umsch 61:521-7. 2004
  9. ncbi [Best supportive care of hepatocellular carcinoma]
    H C Spangenberg
    Abteilung Innere Medizin II, ,
    Internist (Berl) 45:777-85. 2004
  10. ncbi [Diagnosis and treatment of hepatocellular carcinoma]
    H C Spangenberg
    Abteilung Innere Medizin II, ,
    Dtsch Med Wochenschr 129:368-72. 2004

Collaborators

Detail Information

Publications32

  1. ncbi T cell responses in hepatitis C: the good, the bad and the unconventional
    Paul Klenerman
    NIHR Biomedical Research Centre, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK
    Gut 61:1226-34. 2012
    ..Specifically, we will emphasise recent new insights into the effector functions of T cells, possible mechanisms of their failure and the host-virus interactions occurring at the site of the disease, the liver...
  2. ncbi [Hepatology 2007]
    R Thimme
    , Freiburg, Germany
    Dtsch Med Wochenschr 132:1392-5. 2007
  3. ncbi Comprehensive analysis of the alpha-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinoma
    Robert Thimme
    Department of Medicine II, University Hospital Freiburg, Freiburg, Germany
    Hepatology 48:1821-33. 2008
    ..Our results provide support for strategies to boost AFP-specific CD8(+) T cell responses in patients with HCC but also demonstrate a diversity of immune responses that may be needed for protection...
  4. ncbi [Hepatitis B viral load as a risk factor for liver cirrhosis]
    R Thimme
    Abteilung Innere Medizin II,
    Dtsch Med Wochenschr 133:1589-91. 2008
  5. ncbi [Hepatology 2008]
    R Thimme
    Abteilung Innere Medizin II, , Hugstetter Strasse 55, 79106 Freiburg
    Dtsch Med Wochenschr 133:1366-9. 2008
  6. ncbi [The role of the virus specific T-cell response in acute and chronic HBV and HCV infection]
    E Panther
    Abteilung Innere Medizin II, , Germany
    Z Gastroenterol 42:39-46. 2004
    ..In case of viral persistence virus specific T-cells contribute to liver inflammation. In this article we summarize the current concepts about the role of the virus specific T-cell response in acute and chronic HBV and HCV infection...
  7. ncbi [Chronic hepatitis B]
    R Thimme
    , Abteilung Innere Medizin II, Hugstetter Strasse 55, 79106 Freiburg
    Dtsch Med Wochenschr 133:135-8. 2008
  8. ncbi [Cholestatic liver diseases]
    R Thimme
    , Abteilung Innere Medizin II
    Ther Umsch 61:521-7. 2004
    ..Cirrhosis may ultimately develop in PBC and PCS. In progressed PBC or PSC liver transplantation is indicated...
  9. ncbi [Best supportive care of hepatocellular carcinoma]
    H C Spangenberg
    Abteilung Innere Medizin II, ,
    Internist (Berl) 45:777-85. 2004
    ....
  10. ncbi [Diagnosis and treatment of hepatocellular carcinoma]
    H C Spangenberg
    Abteilung Innere Medizin II, ,
    Dtsch Med Wochenschr 129:368-72. 2004
  11. ncbi [Systemic treatment for hepatocellular carcinoma]
    H C Spangenberg
    Abteilung Innere Medizin II, , Germany
    Zentralbl Chir 128:906-10. 2003
    ..Efficient strategies for the primary prevention of HCC are available and promising concepts in the secondary prevention have been reported...
  12. ncbi Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection
    C Neumann Haefelin
    Department of Medicine II, University of Freiburg, Freiburg, Germany
    Genes Immun 8:181-92. 2007
    ..A better understanding of these host-virus interactions is essential not only to gain better insights into the mechanisms of viral clearance and persistence but also for the development of new antiviral vaccine strategies...
  13. ncbi [Suppressor T-cells: immunologic regulator cells and clinical perspectives]
    C Neumann-Haefelin
    Abteilung Innere Medizin II,
    Dtsch Med Wochenschr 129:1627-30. 2004
    ..Regulatory T cells modulate immune responses in different clinical settings. Here, we summarize the role of CD4(+)CD25(+) regulatory T cells in autoimmunity, transplantation, infectious diseases and tumor immunity...
  14. ncbi [T cell response to hepatitis B and C: from viral elimination to hepatocellular carcinoma]
    R Thimme
    Abteilung Innere Medizin II, , Germany
    Dtsch Med Wochenschr 127:2277-9. 2002
  15. ncbi T cell response in hepatitis C virus infection
    C Neumann-Haefelin
    Department of Medicine II, University Hospital Freiburg, Hugstetter Strasse 55, D-79106 Freiburg, Germany
    J Clin Virol 32:75-85. 2005
    ..Recent studies, however, have provided new insights into the mechanisms of viral clearance and persistence that will be discussed in detail...
  16. ncbi [Hepatic resection for hepatocellular carcinoma--results and analysis of the current literature]
    H Neeff
    Universitat Freiburg, Allgemein und Viszeralchirurgie, Freiburg, Germany
    Zentralbl Chir 134:127-35. 2009
    ..In this context, we present our results on liver resection for HCC and a discussion of the current literature about (potentially curative) treatment for HCC...
  17. ncbi Serum markers of hepatocellular carcinoma
    H C Spangenberg
    Department of Medicine II, University Hospital, Freiburg, Germany
    Semin Liver Dis 26:385-90. 2006
    ..For all such proposed markers, however, the clinical usefulness has to be carefully evaluated and validated...
  18. ncbi [Acute hepatitis C. Therapy with interferon alpha-2b]
    R Thimme
    Abteilung Innere Medizin II,
    Internist (Berl) 43:1148-50. 2002
  19. ncbi [Jaundice in an HIV-positive pregnant woman]
    E Panther
    Abteilung Innere Medizin II, Universitatsklinikum Freiburg
    Dtsch Med Wochenschr 133:1560-2. 2008
    ..During a routine pregnancy check-up six months previously, an HIV infection had been diagnosed and antiretroviral therapy was initiated. The patient had moved from Nigeria to Germany two years before and has not been abroad since then...
  20. ncbi [RNA interference as antiviral strategy]
    C Neumann-Haefelin
    Abteilung Innere Medizin II, Universitatsklinikum Freiburg
    Dtsch Med Wochenschr 133:2407-9. 2008
    ..The understanding of the mechanisms of action of miRNA might lead to new antiviral and preventive strategies...
  21. ncbi [The patient as partner -- observations regarding a respectful relationship with sick people]
    K Rosler
    Abteilung Innere Medizin II, Medizinische Universitatsklinik Freiburg
    Dtsch Med Wochenschr 130:2937-9. 2005
  22. ncbi [The hepatocellular carcinoma: alternative therapeutical strategies]
    H C Spangenberg
    Abteilung Innere Medizin II, Medizinische Universitatsklinik, Albert Ludwigs Universitat Freiburg
    Zentralbl Chir 132:322-7. 2007
    ..This review should give an overview of possible alternative therapies in HCC treatment...
  23. ncbi [Cholestatic liver diseases: diagnosis and therapy of primary sclerosing cholangitis]
    O G Opitz
    , Abteilung Innere Medizin II, , Germany
    Dtsch Med Wochenschr 127:1827-30. 2002
  24. ncbi [Cholestatic liver diseases: diagnosis and therapy of primary biliary cirrhosis]
    R Thimme
    , Abteilung Innere Medizin II, , Germany
    Dtsch Med Wochenschr 127:1823-6. 2002
  25. ncbi Immunodominance of HLA-A2-restricted hepatitis C virus-specific CD8+ T cell responses is linked to naive-precursor frequency
    Julia Schmidt
    University Hospital Freiburg, Department of Medicine II, Hugstetter Str 55, 79106 Freiburg, Germany
    J Virol 85:5232-6. 2011
    ..These results indicate for the first time that immunodominance in a human viral infection is linked to naïve-precursor frequency...
  26. ncbi [Therapy of hepatitis B]
    R Thimme
    Abteilung Innere Medizin II, Medizinische Universitatsklinik Freiburg
    Praxis (Bern 1994) 95:1383-8. 2006
    ..The efficacy ot the respective antivirals is affected by virological and clinical parameters, thus requiring individual treatment strategies that will be discussed in detail...
  27. ncbi Determinants of viral clearance and persistence during acute hepatitis C virus infection
    R Thimme
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Rd, La Jolla, CA 92037, USA
    J Exp Med 194:1395-406. 2001
    ....
  28. ncbi [Hepatology]
    R Thimme
    Dtsch Med Wochenschr 133:1559. 2008
  29. ncbi [Viral anti-interferon strategies: mechanisms and clinical impact]
    F Weber
    Abteilung Virologie, ,
    Dtsch Med Wochenschr 128:323-5. 2003
  30. ncbi Immune responses against HCV-NS3 after accidental infection with HCV-NS3 recombinant vaccinia virus
    C Eisenbach
    J Viral Hepat 14:817-9. 2007
  31. ncbi [Immunopathogenesis of viral hepatitis]
    C Neumann Haefelin
    Abteilung Innere Medizin II, Medizinische Universitätsklinik Freiburg i Br
    Praxis (Bern 1994) 96:545-51. 2007
    ..The exact knowledge of the mechanisms contributing to viral clearance and persistence are prerequisite to the successful development of prophylactic and therapeutic immunostrategies...
  32. ncbi Degenerate immunogenicity of an HLA-A2-restricted hepatitis B virus nucleocapsid cytotoxic T-lymphocyte epitope that is also presented by HLA-B51
    R Thimme
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 75:3984-7. 2001
    ..In addition, they could facilitate the development of an epitope-based therapeutic vaccine to terminate chronic HBV infection that could provide a broad and diverse population coverage with a single peptide...